This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
As the sector continues its rapid expansion, with a 7 per cent annual growth rate, the event will highlight the increasing reliance on contract development and manufacturing organisations (CDMOs) in bringing new therapies to market.
For many pharmaceuticalcompanies, with complex, multinational operations, the challenge is devising a net-zero roadmap that is both effective and sustainable. Large energy users such as pharmaceuticalmanufacturers can play an important role in protecting grid stability while enabling more renewable generation.
For certain drug substance and drug product manufacturing processes, PCM can bring opportunities to enhance flexibility and efficiency, lower production costs, cut environmental footprints, accelerate scale-up when needed, improve process control, and reduce potential quality issues, workshop participants reported.
With growing awareness of the environmental impact of pharmaceuticalmanufacturing—such as pollution from toxic discharges—companies must adopt more sustainable practices. One of the primary challenges the industry faces is the inherent resource intensity of pharmaceuticalmanufacturing. As I am also Hon.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content